{"id":"NCT04401293","sponsor":"Northwell Health","briefTitle":"Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients","officialTitle":"Systemic Anticoagulation With Full Dose Low Molecular Weight Heparin (LMWH) Vs. Prophylactic or Intermediate Dose LMWH in High Risk COVID-19 Patients (HEP-COVID Trial)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-04-26","primaryCompletion":"2021-05-14","completion":"2021-05-14","firstPosted":"2020-05-26","resultsPosted":"2021-11-22","lastUpdate":"2021-11-22"},"enrollment":257,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Sars-CoV2","COVID"],"interventions":[{"type":"DRUG","name":"Enoxaparin","otherNames":[]},{"type":"DRUG","name":"Prophylactic/Intermediate Dose Enoxaparin","otherNames":["Unfractionated heparin","dalteparin"]}],"arms":[{"label":"Full Dose LMWH anticoagulation therapy","type":"EXPERIMENTAL"},{"label":"Prophylactic/Intermediate Dose LMWH or UFH therapy","type":"ACTIVE_COMPARATOR"}],"summary":"The aim of this study is to test the hypothesis that prophylaxis of severe COVID-19 patients with treatment dose LMWH leads to better thromboembolic-free outcomes and associated complications during hospitalization than prophylaxis with institutional standard of care with prophylactic to intermediate-doses of UFH or LMWH","primaryOutcome":{"measure":"Composite Outcome of Arterial Thromboembolic Events, Venous Thromboembolic Events and All-cause Mortality at Day 30 ± 2 Days.","timeFrame":"Day 30 ± 2 days","effectByArm":[{"arm":"Full Dose LMWH Anticoagulation Therapy","deltaMin":25,"sd":null},{"arm":"Prophylactic/Intermediate Dose LMWH or UFH Therapy","deltaMin":31,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":6,"countries":["United States"]},"refs":{"pmids":["37591523","35244208","34617959","33591017","33502773"],"seeAlso":["https://doi.org/10.1016/j.jacc.2020.03.031","https://doi.org/10.1016/j.jvsv.2018.08.010","https://doi.org/10.1111/jth.14768","https://doi.org/10.1111/jth.14817","https://doi.org/10.1111/jth.14830","https://doi.org/10.1111/jth.14828","https://doi.org/10.1124/pr.115.011247","https://doi.org/10.1016/j.thromres.2020.04.013","https://doi.org/10.1016/j.jacc.2018.01.033","https://doi.org/10.1002/rth2.12358"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":129},"commonTop":[]}}